Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean Frédéric Blanc, André Cosme de Oliveira, Armando Santoro, Jean‐Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F. Greten, Peter R. Galle, Jean François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, M. Moscovici, D. Voliotis, Jordi Bruix (2008). Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 359(4), pp. 378-390, DOI: 10.1056/nejmoa0708857.
Article286 days agoMolecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Roser Pinyol, Robert Montal, Laia Bassaganyas, Daniela Sia, Tadatoshi Takayama, Gar-Yang Chau, Vincenzo Mazzaferro, Sasan Roayaie, Han Chu Lee, Norihiro Kokudo, Zhongyang Zhang, Sara Torrecilla, Agrin Moeini, Leonardo Rodríguez‐Carunchio, Edward Gane, Chris Verslype, Adina Croitoru, Umberto Cillo, Manuel de la Mata, L. Lupo, Simone I. Strasser, Joong‐Won Park, Jordi Camps, Manel Solé, Swan N. Thung, Augusto Villanueva, Carol Peña, Gerold Meinhardt, Jordi Bruix, Josep M. Llovet (2018). Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 68(6), pp. 1065-1075, DOI: 10.1136/gutjnl-2018-316408.
Article286 days agoPhase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma
Ho Yeong Lim, Philippe Merle, Karl Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Katrin Roth, Diego Reis, Barrett H. Childs, Heiko Krissel, Josep M. Llovet (2018). Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma. Clinical Cancer Research, 24(19), pp. 4650-4661, DOI: 10.1158/1078-0432.ccr-17-3588.
Article286 days agoMolecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial
Roser Pinyol, Robert Montal, T. Takayama, Gar‐Yang Chau, Vincenzo Mazzaferro, S. Roayaie, H.C. Lee, Rtp Poon, N. Kokudo, Z. Zhang, Laia Bassaganyas, Sara Torrecilla, Agrin Moeini, Leonardo Rodríguez‐Carunchio, Edward Gane, Chris Verslype, Adina Croitoru, Umberto Cillo, Manuel de la Mata, L. Lupo, Simone I. Strasser, J.-W. Park, Jordi Camps, María A. Solé, S N Thung, A. Villanueva, Carol E. Peña, G. Meinhart, Jordi Bruix, Josep M. Llovet (2017). Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial. Journal of Hepatology, 66(1), pp. S12-S13, DOI: 10.1016/s0168-8278(17)30287-8.
Article286 days agoPhase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)
Josep M. Llovet, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Heiko Krissel, Ho Yeong Lim (2016). Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC). Spiral (Imperial College London), 63
Article286 days ago